These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

283 related items for PubMed ID: 14563183

  • 21. Experience with the use of low-dose methotrexate for inflammatory bowel disease.
    Soon SY, Ansari A, Yaneza M, Raoof S, Hirst J, Sanderson JD.
    Eur J Gastroenterol Hepatol; 2004 Sep; 16(9):921-6. PubMed ID: 15316419
    [Abstract] [Full Text] [Related]

  • 22.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 23. Induction therapy with the selective interleukin-23 inhibitor risankizumab in patients with moderate-to-severe Crohn's disease: a randomised, double-blind, placebo-controlled phase 2 study.
    Feagan BG, Sandborn WJ, D'Haens G, Panés J, Kaser A, Ferrante M, Louis E, Franchimont D, Dewit O, Seidler U, Kim KJ, Neurath MF, Schreiber S, Scholl P, Pamulapati C, Lalovic B, Visvanathan S, Padula SJ, Herichova I, Soaita A, Hall DB, Böcher WO.
    Lancet; 2017 Apr 29; 389(10080):1699-1709. PubMed ID: 28411872
    [Abstract] [Full Text] [Related]

  • 24.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 25.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 26. 6-thioguanine--efficacy and safety in chronic active Crohn's disease.
    Herrlinger KR, Kreisel W, Schwab M, Schoelmerich J, Fleig WE, Ruhl A, Reinshagen M, Deibert P, Fellermann K, Greinwald R, Stange EF.
    Aliment Pharmacol Ther; 2003 Feb 15; 17(4):503-8. PubMed ID: 12622758
    [Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28. A multicenter, randomized, double-blind trial of everolimus versus azathioprine and placebo to maintain steroid-induced remission in patients with moderate-to-severe active Crohn's disease.
    Reinisch W, Panés J, Lémann M, Schreiber S, Feagan B, Schmidt S, Sturniolo GC, Mikhailova T, Alexeeva O, Sanna L, Haas T, Korom S, Mayer H.
    Am J Gastroenterol; 2008 Sep 15; 103(9):2284-92. PubMed ID: 18671816
    [Abstract] [Full Text] [Related]

  • 29. Azathioprine or 6-mercaptopurine for inducing remission of Crohn's disease.
    Sandborn W, Sutherland L, Pearson D, May G, Modigliani R, Prantera C.
    Cochrane Database Syst Rev; 2000 Sep 15; (2):CD000545. PubMed ID: 10796557
    [Abstract] [Full Text] [Related]

  • 30. Infliximab as a bridge to remission maintained by antimetabolite therapy in Crohn's disease: A retrospective study.
    Chauvin A, Le Thuaut A, Belhassan M, Le Baleur Y, Mesli F, Bastuji-Garin S, Delchier JC, Amiot A.
    Dig Liver Dis; 2014 Aug 15; 46(8):695-700. PubMed ID: 24893686
    [Abstract] [Full Text] [Related]

  • 31. Methotrexate in chronic active Crohn's disease: a double-blind, randomized, Israeli multicenter trial.
    Oren R, Moshkowitz M, Odes S, Becker S, Keter D, Pomeranz I, Shirin H, Reisfeld I, Broide E, Lavy A, Fich A, Eliakim R, Patz J, Villa Y, Arber N, Gilat T.
    Am J Gastroenterol; 1997 Dec 15; 92(12):2203-9. PubMed ID: 9399753
    [Abstract] [Full Text] [Related]

  • 32. Is mycophenolate mofetil an effective alternative in azathioprine-intolerant patients with chronic active Crohn's disease?
    Miehsler W, Reinisch W, Moser G, Gangl A, Vogelsang H.
    Am J Gastroenterol; 2001 Mar 15; 96(3):782-7. PubMed ID: 11280551
    [Abstract] [Full Text] [Related]

  • 33. Efficacy of methotrexate in pediatric Crohn's disease: a French multicenter study.
    Uhlen S, Belbouab R, Narebski K, Goulet O, Schmitz J, Cézard JP, Turck D, Ruemmele FM.
    Inflamm Bowel Dis; 2006 Nov 15; 12(11):1053-7. PubMed ID: 17075346
    [Abstract] [Full Text] [Related]

  • 34. Protocol for a multinational risk-stratified randomised controlled trial in paediatric Crohn's disease: methotrexate versus azathioprine or adalimumab for maintaining remission in patients at low or high risk for aggressive disease course.
    Harris RE, Aloi M, de Ridder L, Croft NM, Koletzko S, Levine A, Turner D, Veereman G, Neyt M, Bigot L, Ruemmele FM, Russell RK, PIBD SETQuality consortium and PIBDnet.
    BMJ Open; 2020 Jul 01; 10(7):e034892. PubMed ID: 32611737
    [Abstract] [Full Text] [Related]

  • 35. Azathioprine versus mesalazine for prevention of postoperative clinical recurrence in patients with Crohn's disease with endoscopic recurrence: efficacy and safety results of a randomised, double-blind, double-dummy, multicentre trial.
    Reinisch W, Angelberger S, Petritsch W, Shonova O, Lukas M, Bar-Meir S, Teml A, Schaeffeler E, Schwab M, Dilger K, Greinwald R, Mueller R, Stange EF, Herrlinger KR, International AZT-2 Study Group.
    Gut; 2010 Jun 01; 59(6):752-9. PubMed ID: 20551460
    [Abstract] [Full Text] [Related]

  • 36. Efficacy of azathioprine in the treatment of chronic active Crohn's disease: prospective one-year follow-up study. German Imurek Study Group.
    Ludwig D, Stange EF.
    Z Gastroenterol; 1999 Nov 01; 37(11):1085-91. PubMed ID: 10604222
    [Abstract] [Full Text] [Related]

  • 37. Remission maintenance by tioguanine in chronic active Crohn's disease.
    Herrlinger KR, Deibert P, Schwab M, Kreisel W, Fischer C, Fellermann K, Stange EF.
    Aliment Pharmacol Ther; 2003 Jun 15; 17(12):1459-64. PubMed ID: 12823147
    [Abstract] [Full Text] [Related]

  • 38.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 39. Azathioprine is superior to budesonide in achieving and maintaining mucosal healing and histologic remission in steroid-dependent Crohn's disease.
    Mantzaris GJ, Christidou A, Sfakianakis M, Roussos A, Koilakou S, Petraki K, Polyzou P.
    Inflamm Bowel Dis; 2009 Mar 15; 15(3):375-82. PubMed ID: 19009634
    [Abstract] [Full Text] [Related]

  • 40. Review article: chronic active disease and maintaining remission in Crohn's disease.
    Kamm MA.
    Aliment Pharmacol Ther; 2004 Oct 15; 20 Suppl 4():102-5. PubMed ID: 15352904
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 15.